NBRV - Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q1 2022 Results - Earnings Call Transcript

Nabriva Therapeutics plc (NBRV) Q1 2022 Earnings Conference Call May 05, 2022 04:30 PM ET Company Participants Dan Dolan - Chief Financial Officer Ted Schroeder - Chief Executive Officer Christine Guico-Pabia - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Thomas Yip - HC Wainwright Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Nabriva Therapeutics First Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, this conference call is being recorded. I would now like to turn the call over to Dan Dolan, Nabriva’s Chief Financial Officer. You may begin. Dan Dolan Thank you, Goshen [Phonetic], and good afternoon, everyone. Welcome to the Nabriva’s conference call and webcast where we will be discussing the first quarter 2022 earnings and providing a

For further details see:

Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q1 2022 Results - Earnings Call Transcript